EGFR and neoplasm: Overexpression of EGFR has been reported in >90% of pancreatic tumours and has also been shown to correlate with poorer prognosis.27 Despite these observations providing a clear rationale for the use of CTX in PaCa, it has so far failed to impart a meaningful clinical benefit in this tumour setting when combined with other frontline agents,28–30 most likely because of the concomitant high frequency of KRAS mutations in this disease.